Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Gastrointestinal 1CNS 1Breast 1

Conditions

Breast Neoplasms 19Neoplasms 11Polycystic Ovary Syndrome 9Neoplasm Metastasis 4Multiple Myeloma 4Melanoma 4Vomiting 3Prostatic Neoplasms 3Leukemia, Myeloid, Acute 3Leiomyoma 3Head and Neck Neoplasms 3Endometrial Neoplasms 3Triple Negative Breast Neoplasms 2Solid Tumors 2Skin Neoplasms 2Sarcoma 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Peripheral Nervous System Diseases 2Ovarian Neoplasms 2Obesity 2Nausea 2Myofibroma 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, B-Cell 2Leukemia 2Insulin Resistance 2Inflammation 2Infertility, Female 2

Interventions

Paclitaxel 328Carboplatin 323Bevacizumab 171Gemcitabine 106liposomal doxorubicin 104pembrolizumab 100Topotecan 94Cyclophosphamide 94olaparib 92Cisplatin 92niraparib 69Docetaxel 57Taxes 52Doxorubicin 51Drug Therapy 45fludarabine 39Filgrastim 39Nivolumab 37Magnetic Resonance Spectroscopy 34Surveys and Questionnaires 33Specimen Handling 33Etoposide 32Hyperthermic Intraperitoneal Chemotherapy 31Blood Specimen Collection 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Cytoreduction Surgical Procedures 25Albumin-Bound Paclitaxel 25durvalumab 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Tablets × Clear all
NCT06887673 2025-03-20

Lipid Mediators & Cancer: Montelukast, SPM, and Almonds

University of South Florida

Phase EARLY_PHASE1 Not yet recruiting
56 enrolled
CNSGastrointestinalGynecologicSarcoma

Brain Neoplasms, Inflammation, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms, Endometrial Neoplasms

NCT05258747 2024-10-03

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

Sandoz

Phase 1 Completed
70 enrolled 13 charts
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡